ESTRO 2025: EMBRACE II results with Prof. Richard Pötter
In this exclusive interview conducted at ESTRO 2025, Prof. Richard Pötter, MD, PhD, Professor Emeritus at the Medical University of Vienna, Austria, shares insights into the latest results from the EMBRACE II multicenter prospective interventional cohort study. Speaking with Maarten ter Mors, SVP and Head of Brachy Solutions at Elekta, on behalf of the EMBRACE collaborative group, Prof. Pötter discusses the clinical significance of the findings, their impact on the treatment of locally advanced cervical cancer, future research directions, and the vital role of education in advancing image-guided brachytherapy.
“Most interesting is that we have outstanding results for survival. We have a 3-year overall survival rate of 87% and progression-free survival of 78%, which is really outstanding […]”, said Prof. Richard Pötter.